Overview of Moderna Inc.

Moderna, Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, that specializes in messenger RNA (mRNA) therapeutics and vaccines. The company trades on the Nasdaq exchange under the ticker MRNA. As of December 25 2025, its share price stood at $31.20. The 52‑week high and low were $48.92 and $22.28, respectively, and the market capitalization was $12.79 billion. The price‑earnings ratio was negative, at –3.88.

Stock Performance Context

  1. Three‑Year Return Analysis
  • On December 22 2022, the closing price was $199.08. An investor who had purchased $1,000 worth of shares at that price would have owned 5,023 shares.
  • By December 24 2025, the price had fallen to $32.75, so the portfolio would be worth $164.51. The investment would have lost $835.49 per dollar invested, amounting to a decline of roughly 83.5 % over three years.
  1. Recent Market Activity
  • The S&P 500 closed the day on December 26 2025 at 6,929.94 points, a change of –0.03 %. The index’s market capitalization was €55.021 billion.
  • Throughout the day, the index fluctuated between a low of 6,921.60 and a high of 6,945.77 points, reflecting a generally flat session.

Moderna’s Position in the 2025 U.S. Equity Market

  • Morningstar Weekly Market Wrap (December 26 2025):

  • The report identified Moderna (MRNA) among the worst performers in the U.S. equity universe covered by Morningstar analysts, alongside Tilray Brands (TLRY), Infosys (INFY), and Kohl’s (KSS).

  • In contrast, other sectors such as Basic Materials and Technology contributed to the broader 2025 rally, with names like Sunrun (RUN), Taboola (TBLA), and Venture Global LNG (VG) posting gains.

  • Sectoral Comparison

  • While the biotechnology sector, represented by Moderna, underperformed, the overall market remained largely unchanged, as evidenced by the S&P 500’s marginal decline and the muted trading volume following the Christmas market closure.

Market‑Wide Influences

  • Precious Metal Volatility (December 26 2025)
  • Silver prices surged over 6 % and platinum over 8 % during the session, driven by a supply crunch in Asian markets.
  • These movements are noted in the context of a broader subdued market environment, where Wall Street traded with thin liquidity and low volumes.

Summary

Moderna’s share price has experienced a significant decline from its three‑year high in late 2022 to its current level in late 2025, resulting in an approximate 83 % loss for an investor who had held the stock since that peak. The company’s performance remained below the broader market, as indicated by Morningstar’s assessment and the flat behavior of the S&P 500 during the relevant trading day. Despite the overall market’s muted activity, the session saw notable volatility in precious metals, reflecting broader economic pressures that may continue to influence investor sentiment in the biotech sector.